BiotechTube

Osilodrostat (Isturisa)

ApprovedRecruiting
2 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Mild Autonomous Cortisol Secretion (MACS)

Conditions

Mild Autonomous Cortisol Secretion (MACS)

Trial Timeline

Feb 2, 2026 → Mar 1, 2029

NCT ID
NCT07247058

About Osilodrostat (Isturisa)

Osilodrostat (Isturisa) is a approved stage product being developed by Recordati for Mild Autonomous Cortisol Secretion (MACS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07247058. Target conditions include Mild Autonomous Cortisol Secretion (MACS).

What happened to similar drugs?

7 of 16 similar drugs in Mild Autonomous Cortisol Secretion (MACS) were approved

Approved (7) Terminated (2) Active (8)
✅Aricept (donepezil hydrochloride) + placeboEisaiApproved
✅Donepezil HClEisaiApproved
✅ElagolixAbbVieApproved
✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved
✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved
✅Rivastigmine PatchNovartisApproved
✅ElidelBayerApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07247058ApprovedRecruiting

Competing Products

20 competing products in Mild Autonomous Cortisol Secretion (MACS)

See all competitors
ProductCompanyStageHype Score
Neurosteroid enantiomerOragenicsPhase 2
32
Ranirestat + PlaceboEisaiPhase 2/3
38
Aricept (donepezil hydrochloride) + placeboEisaiApproved
43
Donepezil HClEisaiApproved
43
Donanemab + AducanumabEli LillyPhase 3
40
PPAR alpha + Hydrochlorothiazide + PlaceboEli LillyPhase 2
35
ElagolixAbbVieApproved
35
AZD1446 + PlaceboAstraZenecaPhase 2
35
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous InjectionAstraZenecaPhase 1
29
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved
43
AZD5213 + AZD5213 + AZD5213AstraZenecaPhase 2
35
budesonide/formoterol (Symbicort)AstraZenecaPhase 3
40
MK-8931MerckPhase 1
29
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
26
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)MerckPhase 3
32
Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved
43
LCZ696 + SildenafilNovartisPhase 2
35
QCZ484 + PlaceboNovartisPhase 1
29
Rivastigmine PatchNovartisApproved
43
AFQ056NovartisPhase 1
29